Grail rallies 30% in wake of Quest agreement
Grail (GRAL) stock shot up 33% Thursday, the day after the company announced a partnership with Quest (DGX) to expand ...
Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability
The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...
Business Insider4d
Illumina downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...
Business Insider4d
Illumina downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to management’s ability to deliver on their plan due ...
Yahoo Finance3d
GRAIL, Inc. (GRAL)
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company ... Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index.
Companion Diagnostics Market Trends 2019-2024 and Forecast to 2034 - Rising Number of Targeted Therapies Driving the $8.75 Billion Industry
Companion Diagnostics Market Companion Diagnostics Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Companion ...
pharmaphorum4d
ASCO: Grail’s cancer blood test ‘promising’ in UK trial
That merger has been challenged by antitrust regulators concerned that Illumina has gained an unfair position in the market, and is under threat of being dismantled. According to Grail’s Europe ...
pharmaphorum2d
NHS England starts largest ever trial of Galleri cancer blood test
Volunteers aged between 50 and 77 are being sought to trial the diagnostic developed by California biotech Grail, which spun out of Illumina in 2016 and agreed to be reacquired by the lab ...